Efficacy of Aspirin in the treatment of schizophrenia

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108197373N1

Enrollment

Registered

2011-10-17

Start date

2011-10-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia, schizotypal and delusional disorders.

Interventions

Intervention 1: Intervention group recieve an atypical antipsychotic plus Aspirin 1000mg/day for 8 weeks. Intervention 2: Control group recieve an atypical antipsychotic plus plasebo for 8 weeks (wi

Treatment - Drugs

Intervention group recieve an atypical antipsychotic plus Aspirin 1000mg/day for 8 weeks

Control group recieve an atypical antipsychotic plus plasebo for 8 weeks (with the same dose and shape).

Eligibility

Sex/Gender

All

Age

15 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age range 15-55, diagnosis of schizophrenia according to DSM4-TR criteria and clinical interview by psychiatrist, signing written informed consent, a score of at least 60 in PANSS Exclusion criteria: pregnancy, substance abuse, severe physical disease such as kidney disease, coagulation disorders, GI disorders such as peptic ulcer, contraindications of Aspirin and inhibitors of proton pump

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
PANSS. Timepoint: Before invention and every two weeks. Method of measurement: Clinical examination.	—

Secondary

Measure	Time frame
Extrapyramidal and GI side effect. Timepoint: Before invention and every two weeks. Method of measurement: Clinical examination.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026